According to our new market research study on “Smoking Cessation Aids Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, End User, and Geography,” the market is expected to reach US$ 64,032.30 million in 2028 from US$ 23,413.08 million in 2021. The market is estimated to grow with a CAGR of 15.5% from 2021-2028. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking, increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.
Based on end-user, the smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, however the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.
Get Sample PDF Copy of Smoking Cessation Aids Market at:
https://www.theinsightpartners.com/sample/TIPRE00023325/
The substance and tobacco abuse treatment industry is getting competitive every consecutive year with the introduction of new and innovative therapies by the smoking cessation aids market players. For instance, in July 2020, Dr Reddy’s Laboratories announced the launch of over-the-counter Nicotine Polacrilex lozenges in the American market. The company launched Nicotine Polacrilex lozenges in the strengths of 2 mg and 4 mg in the US. Furthermore, the top players in the market are also collaborating with third parties to improve their existing product range of smoking cessation aids. For instance, in March 2016, GlaxoSmithKline partnered with a digital smoking cessation company 2Morrow to offer the GSK’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
In addition, medical devices such as nicotine-free e-cigarettes and vapes are being launched by market players at local and regional levels. For instance, the US based electronic cigarette company Juul Labs announced to launch its products in India by the end of 2019. In December 2018, the British American Tobacco (BAT) introduced two new e-cigarettes named Vype iSwitch Maxx and Vype iSwitch in five of BAT’s VIP stores in London. Thus, the consistent launch of new and innovative smoking cessation aids would become a prevalent trend in the smoking cessation aids market in the coming years.
COVID-19 outbreak was first observed in December 2019 in Wuhan (China), and it has spread to more than 100 countries across the world, with the World Health Organization (WHO) stating it as a public health emergency. The global impacts of COVID-19 are being felt across several markets. The findings show that e-cigarette usage and dual use of e-cigarettes and cigarettes are important underlying risk factors for COVID-19 that have previously not been established. As per the researchers, smoking is a risk factor for influenza, patients who smoke are immunosuppressed to some degree, and they make more mucus.
Pfizer Inc.; GlaxoSmithKline plc.; Dr. Reddy’s Laboratories; Johnson and Johnson Services, Inc.; Cipla Inc.; Perrigo Company plc; Bausch Health Companies Inc.; Glenmark; NJOY; and Juul Labs are among the leading companies operating in the smoking cessation aids market.
Speak to Analyst for more details:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00023325
The Report Segments Global Smoking Cessation Aids Market as Follows:
By Product
Nicotine Replacement Therapy
Drugs
Electronic Cigarettes
Others
By End User
Hospital Pharmacies
Online Channel
Retail Pharmacies
Others
By Geography
North America
US
Canada
Mexico
Europe
France
Germany
UK
Spain
Italy
Asia Pacific (APAC)
China
India
Japan
Australia
South Korea
Middle East and Africa (MEA)
Saudi Arabia
UAE
South Africa
South and Central America (SCAM)
Brazil
Argentina
Order a Copy of Smoking Cessation Aids Market Shares, Strategies and Forecasts 2021-2028 Research Report at:
https://www.theinsightpartners.com/buy/TIPRE00023325/
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Healthcare, Media, and Telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused toward market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, type, end-users, etc., which helps our clients to gain a deeper analytical understanding of various research topics.
Contact Us
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
AsiaPacific: +91 20 6727 8686
Email: [email protected]
Press Release: https://www.theinsightpartners.com/pr/smoking-cessation-aids-market
